IPP Bureau
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
By IPP Bureau - March 29, 2025
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
By IPP Bureau - March 29, 2025
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
WeylChem strengthens custom manufacturing with unified leadership
By IPP Bureau - March 27, 2025
Dr. Benjamin Bechem, already leading WeylChem Organica and European custom manufacturing sales
European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease
By IPP Bureau - March 27, 2025
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Bio-Thera & Dr Reddy’s execute commercialization pact for biosimilars Stelara & Simponi for SE Asia
By IPP Bureau - March 27, 2025
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
GSK, UK Dementia Research Institute and Health Data Research UK to collaborate on first-of-its-kind dementia research initiative
By IPP Bureau - March 27, 2025
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Innovaoleo launches Omega 3 Star for food, nutraceutical and pet nutrition
By IPP Bureau - March 27, 2025
Omega 3 oil 18 EPA/12 DHA is highly demanded worldwide for its multiple benefits for human and animal health
Merck and Zebra Technologies collaborate to create safety and traceability solutions
By IPP Bureau - March 27, 2025
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
Mila Beaute raises $2.16 million in pre-series A round led by Rukam Capital
By IPP Bureau - March 27, 2025
The freshly infused capital will primarily be deployed towards expansion and research & development
Abbott launches intravascular lithotripsy trial aimed at clearing coronary arteries
By IPP Bureau - March 27, 2025
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
Glenmark launches nutrition program to fight malnutrition in Philippines
By IPP Bureau - March 26, 2025
This program, titled "Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan," aligns with the country’s national health
Alembic Pharma and Amlan International partner to advance poultry health in India
By IPP Bureau - March 26, 2025
Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators
Merck inks $200 million deal for Hengrui's midstage heart disease drug
By IPP Bureau - March 26, 2025
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Wipro announces AI Agent Solutions across healthcare industry
By IPP Bureau - March 25, 2025
Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies














